AWM
WHWK

Avior Wealth Management’s Whitehawk Therapeutics WHWK Stock Holding History

Avior Wealth Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$7 – 3810
2024
Q1 		$7 Buy
+3
New +$6 ﹤0.01% 3794

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Avior Wealth Management's WHWK Position: Q2 2024 in Review

Avior Wealth Management sold out of Whitehawk Therapeutics (WHWK) in Q2 2024, closing a stake of 3 shares — an estimated $7 sold.

Avior Wealth Management first reported a position in WHWK in Q1 2024 and held it in 1 quarter. The position peaked at $7 in Q1 2024. 65 funds tracked by Wall St. Rank hold WHWK as of Q2 2024.

  • Avior Wealth Management reported no remaining Whitehawk Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 3 Whitehawk Therapeutics shares in Q2 2024, an estimated $7.
  • Avior Wealth Management first reported a position in Whitehawk Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Whitehawk Therapeutics position peaked at $7 in Q1 2024.
  • 65 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.